



Innovative Cell and Tissue Technology

Press Release
January 14, 2011
Gothenburg

Vitrolife obtains patent for Swemed Sense™ in Europe

Swemed Sense™ is a unique needle that is used for the collection of oocytes in connection with IVF. The approved patent means that Vitrolife has both design protection and product patent protection for Swemed Sense™ in strategically important European markets. A patent has also been applied for in other prioritized markets.

A recently presented study shows that Swemed Sense™ gives less pain and bleeding during the collection of oocytes, compared with a conventional needle.

Swemed Sense™ has a unique design, as advantages from both thin and thick needles are combined in one and the same needle. Swemed Sense™ is designed with a thinner front part and tip so as to minimize tissue damage, bleeding and pain. The rear part of the needle has a larger diameter, which means that the needle is stable and at the same time maintains flow and speed.

The market for needles used in the collection of oocytes for IVF is estimated to amount to approximately 40 million Euros globally.

January 14, 2011
Gothenburg

Magnus Nilsson
CEO

Queries should be addressed to:

Magnus Nilsson, CEO, phone +46 31 721 80 61
Anne-Lie Sveder, CFO, phone +46 31 721 80 13

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body in order to select usable organs and keep them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are sold in more than 85 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France, Italy, United Kingdom and Japan. Production facilities are located in Sweden and the USA. The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com. Website: www.vitrolife.com